Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today anno

Magenta Medical has secured $105 million in a financing round led by Novo Holdings, with participation from Viking Global Investors, RA Capital Management, and existing investors like OrbiMed and New Enterprise Associates. The funds will support US clinical programs and FDA approval pursuits for the Elevate heart pump, designed for high-risk percutaneous coronary interventions. The Elevate System, noted for its small size and high power, has received Breakthrough Device Designation from the FDA.

Israeli startup aims to compete with U.S. heart-pump pioneer Abiomed, now owned by Johnson & Johnson. But analysts say the market has lots of room to grow.